Photo of Eran Chemerinski

Eran Chemerinski

Print ProfilePrint Profile


  • 2005 -
    Kenneth L. Davis M.D. Award for Research Excellence in Psychiatry
    Mount Sinai School of Medicine

  • 2005 -
    APA/Lilly Resident Research Award
    American Psychiatric Association

  • 2003 -
    NIMH Outstanding Resident Award
    National Institute of Mental Health

  • 2000 -
    Young Investigator Award
    American Neuropsychiatric Association




Chemerinski E, Harvey P, Anderson H, Bowie A. Depression in Schizophrenia: Methodological Artifact or Distinct Feature of the Illness?. J Neuropsychiatry Clin Neurosci 2008;.

Chemerinski E, Reichenberg A, Harvey P, Bowie C, Kirkpatrick B. Three Dimensions of Clinical Symptoms in Elderly Patients with Schizophrenia: Prediction of Six-year Cognitive and Functional Status. Schizophrenia Res 2006 July; 85: 12-19.

Chemerinski E, Ho BC, Andreasen NC, Arndt S, Fleming F, Flaum M. Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Compr Psychiatry 2002 Sep-Oct; 43(5): 393-396.

Chemerinski E, Nopoulos PC, Magnotta V, Andreasen NC, Crespo-Facorro B. Morphology of the ventral frontal cortex in schizophrenia: relationship with social dysfunction. Biol Psychiatry 2002 Jul 1; 52(1): 1-8.

Chemerinski E, Robinson RG, Arndt S, Kosier JT. The effect of remission of poststroke depression on activities of daily living in a double-blind randomized treatment study. J Nerv Ment Dis 2001 Jul; 189(7): 421-5.

Chemerinski E, Robinson RG, Kosier JT. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke 2001 Jan; 32(1): 113-7.

Chemerinski E, Petracca G, Sabe L, Kremer J, Starkstein SE. The specificity of depressive symptoms in patients with Alzheimer's disease. Am J Psychiatry 2001 Jan; 158(1): 68-72.

Robinson RG, Chemerinski E. The neuropsychiatry of stroke. Psychosomatics 2000 Jan-Feb; 41(1): 5-14.

Chemerinski E, Petracca G, Starkstein SE, Sabe L, Leiguarda R, Teson A. Prevalence and correlates of aggressive behavior in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1998 Fall; 10(4): 421-425.

Chemerinski E, Petracca G, Manes F, Leiguarda R, Starkstein SE. Prevalence and correlates of anxiety in Alzheimer's disease. Depress Anxiety 1998; 7(4): 166-170.

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.

Dr. Chemerinski did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Edit profile in Sinai Central


Annenberg Building
1468 Madison Avenue
New York, NY 10029

Tel: 212-659-8752